Alpine Immune Sciences Stock Price, News & Analysis (NASDAQ:ALPN)

$9.70 0.00 (0.00 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$9.70
Today's Range$9.48 - $9.79
52-Week Range$7.20 - $14.52
Volume21,386 shs
Average Volume11,451 shs
Market Capitalization$134.65 million
P/E Ratio-1.12
Dividend YieldN/A
BetaN/A

About Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences logoNivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company's lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Debt-to-Equity Ratio0.05%
Current Ratio32.38%
Quick Ratio32.38%

Price-To-Earnings

Trailing P/E Ratio-1.12080924855491
Forward P/E Ratio-8.36
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$14.27 per share
Price / Book0.68

Profitability

Trailing EPS($8.65)
Net Income$-31,460,000.00
Net MarginsN/A
Return on Equity-39.40%
Return on Assets-36.05%

Miscellaneous

Employees15
Outstanding Shares13,880,000

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings data on Monday, February, 13th. The biotechnology company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. During the same period in the prior year, the company earned ($0.42) EPS. View Alpine Immune Sciences' Earnings History.

Where is Alpine Immune Sciences' stock going? Where will Alpine Immune Sciences' stock price be in 2018?

2 brokers have issued 12 month target prices for Alpine Immune Sciences' shares. Their predictions range from $17.00 to $17.00. On average, they expect Alpine Immune Sciences' share price to reach $17.00 in the next twelve months. View Analyst Ratings for Alpine Immune Sciences.

Who are some of Alpine Immune Sciences' key competitors?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the folowing people:

  • Howard P. Furst M.D., Chairman of the Board
  • R. Michael Carruthers, Interim President, Chief Financial Officer, Secretary
  • Janice M. Troha, Chief Operating Officer
  • Sherif Gabriel Ph.D., Vice President – Research and Discovery
  • Steven Shoemaker M.D., Vice President – Clinical Research and Development, Medical Director
  • Robert E. Conway, Independent Director
  • Evan Loh M.D., Independent Director
  • John R. Moore, Independent Director
  • Paul Sekhri, Independent Director

Who owns Alpine Immune Sciences stock?

Alpine Immune Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.49%), Victory Capital Management Inc. (0.37%), Millennium Management LLC (0.13%), Spark Investment Management LLC (0.12%) and Wells Fargo & Company MN (0.08%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, David Malcom Rodman, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.

Who sold Alpine Immune Sciences stock? Who is selling Alpine Immune Sciences stock?

Alpine Immune Sciences' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. View Insider Buying and Selling for Alpine Immune Sciences.

Who bought Alpine Immune Sciences stock? Who is buying Alpine Immune Sciences stock?

Alpine Immune Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Victory Capital Management Inc. and Wells Fargo & Company MN. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.

How do I buy Alpine Immune Sciences stock?

Shares of Alpine Immune Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of Alpine Immune Sciences stock can currently be purchased for approximately $9.70.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $134.65 million. The biotechnology company earns $-31,460,000.00 in net income (profit) each year or ($8.65) on an earnings per share basis. Alpine Immune Sciences employs 15 workers across the globe.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (ALPN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alpine Immune Sciences (NASDAQ:ALPN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.332.43
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.00$17.00$7.31$10.88
Price Target Upside: 543.94% upside543.94% upside176.99% upside311.93% upside

Alpine Immune Sciences (NASDAQ:ALPN) Consensus Price Target History

Price Target History for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ:ALPN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$17.00LowView Rating Details
4/19/2017CowenReiterated RatingHoldMediumView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$30.00 -> $6.00N/AView Rating Details
11/29/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
11/29/2016Robert W. BairdDowngradeOutperform -> Neutral$29.00 -> $3.00N/AView Rating Details
11/29/2016Stifel NicolausDowngradeBuy -> Hold$16.00 -> $3.25N/AView Rating Details
8/30/2016Piper Jaffray CompaniesReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Alpine Immune Sciences (NASDAQ:ALPN) Earnings History and Estimates Chart

Earnings by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ ALPN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.62)($0.19)$0.13 millionViewN/AView Earnings Details
7/21/2017Q2 2017($0.96)($0.72)ViewN/AView Earnings Details
5/9/2017Q1 2017($2.24)($2.24)$29.98 millionViewN/AView Earnings Details
2/13/2017Q4 16($0.55)($0.50)ViewN/AView Earnings Details
11/7/2016Q3($0.59)($0.48)ViewN/AView Earnings Details
8/1/2016Q2($0.52)($0.55)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.39)($0.39)ViewN/AView Earnings Details
8/3/2015Q2 2015($0.40)($1.41)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Alpine Immune Sciences (NASDAQ:ALPN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS

Dividends

Dividend History for Alpine Immune Sciences (NASDAQ:ALPN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alpine Immune Sciences (NASDAQ ALPN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 56.63%
Insider Trades by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)
Institutional Ownership by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ ALPN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/20/2017Value Fund L P BiotechnologyInsiderBuy17,806$2.25$40,063.50View SEC Filing  
6/7/2017Bvf Partners L P/IlMajor ShareholderBuy36,900$2.28$84,132.00View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy72,650$2.29$166,368.50View SEC Filing  
6/5/2017Bvf Partners L P/IlMajor ShareholderBuy35,750$2.29$81,867.50View SEC Filing  
5/31/2017Value Fund L P BiotechnologyInsiderBuy47,000$2.27$106,690.00View SEC Filing  
5/19/2017Value Fund L P BiotechnologyInsiderBuy78,858$2.30$181,373.40View SEC Filing  
5/11/2017Value Fund L P BiotechnologyInsiderBuy109,034$2.32$252,958.88View SEC Filing  
5/9/2017Robert E ConwayDirectorBuy5,000$2.34$11,700.0045,000View SEC Filing  
5/8/2017Robert E ConwayDirectorBuy15,000$2.28$34,200.0060,000View SEC Filing  
5/5/2017Janice TrohaEVPBuy10,000$2.34$23,400.0010,000View SEC Filing  
5/5/2017Robert E ConwayDirectorBuy20,000$2.30$46,000.0040,000View SEC Filing  
5/4/2017Robert E ConwayDirectorBuy10,000$2.26$22,600.0020,000View SEC Filing  
1/4/2017David Malcom RodmanEVPSell6,687$2.27$15,179.4918,055View SEC Filing  
12/2/2016R Michael CarruthersEVPBuy24,000$2.09$50,160.0024,000View SEC Filing  
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.2018,056View SEC Filing  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.0018,055View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.0020,000View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.0015,000View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.0010,000View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.005,000View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.0010,000View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alpine Immune Sciences (NASDAQ ALPN) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per ShareZacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - February 13 at 5:24 AM
Alpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of "Hold" by AnalystsAlpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 30 at 5:18 PM
Alpine Immune Sciences (ALPN) Downgraded by Zacks Investment ResearchAlpine Immune Sciences (ALPN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
Alpine Immune Sciences (ALPN) Lifted to "Buy" at Zacks Investment ResearchAlpine Immune Sciences (ALPN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 5:50 PM
Alpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment ResearchAlpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - January 4 at 5:52 PM
Alpine Immune Sciences (ALPN) Cut to Hold at Zacks Investment ResearchAlpine Immune Sciences (ALPN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
ValuEngine Upgrades Alpine Immune Sciences (ALPN) to SellValuEngine Upgrades Alpine Immune Sciences (ALPN) to Sell
www.americanbankingnews.com - December 31 at 12:46 AM
Alpine Immune Sciences (ALPN) Upgraded by Zacks Investment Research to BuyAlpine Immune Sciences (ALPN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 26 at 5:29 PM
Zacks: Analysts Expect Alpine Immune Sciences, Inc. (ALPN) to Post -$0.44 EPSZacks: Analysts Expect Alpine Immune Sciences, Inc. (ALPN) to Post -$0.44 EPS
www.americanbankingnews.com - December 24 at 7:16 PM
Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host DiseaseAlpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
finance.yahoo.com - December 19 at 8:55 AM
Alpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of "Hold" from BrokeragesAlpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 6:28 PM
Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor CellsAlpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
finance.yahoo.com - December 6 at 9:05 AM
Nivalis Therapeutics, Inc. (ALPN) Given Average Rating of "Hold" by AnalystsNivalis Therapeutics, Inc. (ALPN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 3:50 PM
Nivalis Therapeutics, Inc. (ALPN) Stock Rating Upgraded by Zacks Investment ResearchNivalis Therapeutics, Inc. (ALPN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM
Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial ResultsAlpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 2:50 AM
Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual MeetingAlpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
finance.yahoo.com - November 10 at 2:28 PM
Nivalis Therapeutics (ALPN) & The Competition Critical ReviewNivalis Therapeutics (ALPN) & The Competition Critical Review
www.americanbankingnews.com - November 7 at 5:34 AM
Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and InflammationAlpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
finance.yahoo.com - November 6 at 4:34 PM
Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in NovemberAlpine Immune Sciences to Present at Two Upcoming Investor Conferences in November
finance.yahoo.com - November 1 at 4:12 PM
Zacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong SellZacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong Sell
www.americanbankingnews.com - October 26 at 7:24 PM
Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRsAlpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs
finance.yahoo.com - October 23 at 4:51 PM
Nivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of "Hold" by AnalystsNivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 22 at 4:44 PM
Alpine Immune Sciences Announces Upcoming Scientific PresentationsAlpine Immune Sciences Announces Upcoming Scientific Presentations
finance.yahoo.com - October 16 at 4:35 PM
Impel NeuroPharma names CEOImpel NeuroPharma names CEO
www.bizjournals.com - October 6 at 4:21 AM
Nivalis Therapeutics, Inc. (ALPN) Raised to Buy at Stifel NicolausNivalis Therapeutics, Inc. (ALPN) Raised to Buy at Stifel Nicolaus
www.americanbankingnews.com - September 22 at 7:44 AM
Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual MeetingAlpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
finance.yahoo.com - September 20 at 3:41 PM
Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare ConferenceAlpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 13 at 4:51 PM
Nivalis Therapeutics, Inc. (ALPN) Receives Average Rating of "Hold" from AnalystsNivalis Therapeutics, Inc. (ALPN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 2 at 7:16 PM
-$0.28 EPS Expected for Nivalis Therapeutics, Inc. (ALPN) This Quarter-$0.28 EPS Expected for Nivalis Therapeutics, Inc. (ALPN) This Quarter
www.americanbankingnews.com - August 15 at 6:06 PM
Strength Seen in FibroGen (FGEN): Stock Soars 48.2%Strength Seen in FibroGen (FGEN): Stock Soars 48.2%
finance.yahoo.com - August 9 at 3:55 PM
Nivalis Therapeutics, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from BrokeragesNivalis Therapeutics, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 8 at 6:44 PM
Corcept (CORT) Looks Good: Stock Moves Up 8.8% in SessionCorcept (CORT) Looks Good: Stock Moves Up 8.8% in Session
finance.yahoo.com - August 3 at 4:45 PM
Alpine Immune Sciences, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial ServicesAlpine Immune Sciences, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - July 27 at 9:24 AM

SEC Filings

Alpine Immune Sciences (NASDAQ:ALPN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alpine Immune Sciences (NASDAQ:ALPN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alpine Immune Sciences (NASDAQ ALPN) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.